<DOC>
	<DOCNO>NCT01154231</DOCNO>
	<brief_summary>The survey intend investigate following matter , etc . actual use status marketing patient administer drug certain period time launch . 1 . Occurrence status adverse event 2 . Factors may influence safety 3 . Efficacy In addition , follow occurrence status investigate priority item survey : Incidence rate inhibitor , reduction drug , efficacy , Allergic reaction , Thrombosis .</brief_summary>
	<brief_title>BeneFIX Drug Use Results Survey All-Case Surveillance</brief_title>
	<detailed_description>Patients hemophilia B ( congenital blood coagulation factor IX deficiency ) administer drug . Patients hemophilia B either patient treatment already start blood coagulation factor IX product ( `` Previously treat patient '' : hereinafter , `` PTPs '' ) patient history treatment blood coagulation factor IX product past treatment start drug first time ( `` Previously untreated patient '' : hereinafter , `` PUPs '' ) . The definition PUPs survey `` Patients total number day administration blood coagulation factor IX product drug administration drug 3 exposure day ( actual number day administration : hereinafter , `` EDs '' ) less . ''</detailed_description>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>All patient hemophilia B schedule receive treatment BeneFIX eligible surveillance . No patient exclude prior inhibitor history ; however , complete patient history demographic collect . Patients administer BeneFIX .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>BeneFIX Regulatory Post Marketing Commitment Plan</keyword>
</DOC>